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De novo metastatic breast carcinoma is breast cancer that has already metastasized before the initial 
diagnosis. Most commonly breast cancer spreads to the liver, brain, bones, and lungs. If the primary 
tumor is never found the cancer is labeled an occult primary. A 55-year-old woman presented with 
bilateral knee pain, fever, anemia and elevated inflammatory markers. MSCT showed multiple 
osteolytic lesions, and malignant cells were found in the bone marrow and ascites. First line treatment 
with paclitaxel and carboplatin was started in 06/2014. Simultaneously, pamidronate was initiated for 
the osteolytic lesions. After a year, it was replaced by zoledronate. Therapy success was evaluated by 
monitoring tumor markers, CEA, Ca125 and Ca15-3. Letrozole was chosen as next line treatment in 
12/2014, because the earlier biopsy showed that the cancer was HR+, Her2/neu-. Because of new lesions 
in the liver, in 09/2016 letrozole was replaced with tamoxifen. An increase in tumor markers in 02/2018 
prompted the next lines of treatment, first with fulvestrant, 8 cycles, and afterwards, exemestane for a 
month. In 07/2018 she began treatment with paclitaxel, 4 cycles. Doxorubicin has been prescribed in 
11/2018 as a last line treatment, to which she has been responding positively. Advanced breast cancer 
is a multisystem disease whose treatment is difficult and long. In this case, the patient has been 
undergoing treatment for 5 years. Her treatment regimen was planned in accordance with the standard 
guidelines for breast carcinomas with the same characteristics, as if the primary tumor had been found 
in the breast. 
 
  
